Navigation Links
Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
Date:11/25/2008

Dr. Leonel Fernandez Liriano, Professor of Medicine at Pontifical Catholic University School of Medicine (PCUSM), announced nine month follow up results for the first patient treated with engineered stem cells in a clinical study of primary pulmonary hypertension. The stem cells are extracted from patients’ own blood and trained to become new blood vessels.

SANTO DOMINGO, Dominican Republic (Business Wire EON) November 25, 2008 -- Zannos Grekos, M.D., Assistant Clinical Professor of Cardiology at Nova Southeastern University and head of the international team that developed the stem cell treatment protocol, says, "It goes against traditional theory that we should try to fix the existing pulmonary vasculature, but we are generating new blood vessels with impressive results." According to Grekos, the clinical study is a collaborative effort amongst physicians at Regenocyte Therapeutic, a Florida-based stem cell clinic; researchers from TheraVitae, a biotechnology company in Tel Aviv, Israel; and physicians from Regenocyte's Dominican Republic division. The patient's base line and follow up testing is being conducted in part by Mayo Clinic, Jacksonville, Florida.

Patient Karl Wagner, age 46 of Macon, Georgia, underwent the Adult Stem Cell therapy in February 2008. Wagner says since being diagnosed with pulmonary hypertension, he was on a rapid decline. "I was being managed by medication, but still had violent chest pains, heart palpitations, extreme fatigue, and severe shortness of breath…I could barely do anything with my daughters and was on oxygen almost all the time. Doctors at Mayo Clinic gave me a three year prognosis."

  • Hctor Jos Rosario, Professor of Cardiology at PCUSM and Director of Cardiovascular Therapy for Regenocyte's Dominican division, says Wagner's reduction in pulmonary artery mean pressure from 41mmHg (severe pulmonary hypertension) to 24 mmHg (normal) is extremely encouraging, and to date, the other patients in the study are following the same pattern.

"This is the first time medical science has successfully reversed the disease process in pulmonary hypertension, a previously untreatable condition with a very grim prognosis," Rosario states.

"Using advanced engineered stem cell technology and innovative delivery methods," Grekos explains, "we've been able to harness the regenerative power of stem cells and literally replace the damaged blood vessels in the lungs of the pulmonary hypertension patients."

Wagner's saturations are now consistently high, and he no longer needs to be supplemented with oxygen or considered for a lung transplant. "I feel great," he says, "and have a normal life again. I take my girls to school every morning and work all day…my quality of life is ten-fold what it used to be. I also am off almost all of my medications and the doctors at Mayo Clinic have given me a new prognosis."

Athina Kyritsis, M.D. and chair of Regenocyte's Scientific Advisory Board, says the work announced today is based upon several years of Regenocyte's clinical experience in the treatment of cardiac and vascular disease using Autologous Adult Stem Cell therapy. "In treating diseases like Cardiomyopathy and Peripheral Vascular Disease, we've had consistent success in generating viable heart tissue and growing new vessels; with the increased circulation, healing of wounds, and improvement in ejection fractions, it seemed a natural progression to approach pulmonary hypertension in the same manner. I believe we have only begun to discover what Adult Stem Cells can accomplish in altering the course of diseases now thought to be untreatable."

About the Alliance for the Advancement of Adult Stem Cell Therapy and Research

  • Alliance for the Advancement of Adult Stem Cell Therapy and Research is a non-profit organization dedicated to promoting the use of adult stem cells in the research and treatment of life-altering diseases. This alliance also strives to ensure treatment for those who qualify and could not otherwise afford to receive it. To become a supporting member, please call (239) 498-9187.

About Regenocyte

Regenocyte Therapeuticis one of the only clinically treating Adult Stem Cell Therapy centers in the world today. An experienced team of Board Certified physicians use cutting edge technology, paralleling that of Universities and major medical facilities, to prolong and improve the quality of life of patients living with diseases including Congestive Heart Failure, Cardiomyopathy, Peripheral Artery Disease, Coronary Artery Disease, Kidney Disease, Ischemic Heart Disease, Pulmonary Disease, and Early Senile Dementia. For patient information or consultation, call 866-216-5710.

Read the full story at http://www.prweb.com/releases/stem_cell/adult_stem/prweb1671234.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act Increases to 27 Members
2. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
3. Women at Higher Risk for Pulmonary Hypertension
4. Cialis May Help Ease Pulmonary Hypertension
5. Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
6. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
7. The U.S. Surgeon General Issues National Call-to-Action on Deep-Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
8. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
9. American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act
10. Simple Case Management Cuts Pulmonary Disease Admissions
11. A guided broncoscope achieves biopsy of 75 percent pulmonary nodules without puncture or surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and ... in Mystic, CT. Covering the process and maintenance strategies of gum grafting and ... periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists in ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: